BioSpace News Archive

Business

CN Bio appoints Dr Paul Brooks as Chief Executive Officer

CN Bio, a leading Organ-on-a-chip Company that designs and manufactures single-and multi-organ microphysiological systems, announced the appointment of Dr Paul Brooks, formerly the Company’s Chief Business Officer, to the position of CEO with immediate effect.

December 19, 2022
·
3 min read
Drug Development

atai Life Sciences Initiates Phase 2b proof-of-concept trial of RL-007 for Cognitive Impairment Associated with Schizophrenia

The phase 2b proof-of-concept trial will evaluate the novel compound, RL-007, for pro-cognitive effects in patients with Cognitive Impairment Associated with Schizophrenia (CIAS).

December 19, 2022
·
8 min read
Business

REGENATIVE LABS SEEKING COLLABORATION IN AN OBSERVATIONAL SHOULDER STUDY TO ACHIEVE BETTER PATIENT OUTCOMES

Regenative Labs (Regenative), a leading HCT/P manufacturer, seeks collaboration from physicians who commonly see tissue defects of the shoulder.

December 19, 2022
·
3 min read
Drug Development

PureTech’s LYT-300 (Oral Allopregnanolone) Demonstrates Oral Bioavailability, Tolerability and GABAA Receptor Target Engagement in Healthy Volunteers

PureTech’s LYT-300 (Oral Allopregnanolone) Demonstrates Oral Bioavailability, Tolerability and GABA A Receptor Target Engagement in Healthy Volunteers.

December 19, 2022
·
11 min read
Business

Enzolytics, Inc. Announces the Completion of the 2020 and 2021 Audited Financials

Enzolytics, Inc. (OTC PINK:ENZC) ( https://enzolytics.com/ ). Enzolytics, Inc. announces the completion of the 12/31/2020 and 12/31/2021 audited financials.

December 19, 2022
·
5 min read
Business

ADC Therapeutics Appoints Jose Carmona as Chief Financial Officer

ADC Therapeutics SA (NYSE: ADCT) today announced the appointment of Jose “Pepe” Carmona as Chief Financial Officer (CFO), effective December 19, 2022.

December 19, 2022
·
4 min read
Genetown

Paratek Pharmaceuticals Announces Positive Top Line Data from Pilot Efficacy Study for the Treatment of Pulmonary Anthrax and Acceptance of the Second Procurement of NUZYRA® (omadacycline) under BARDA Project BioShield

Paratek Pharmaceuticals, Inc. (NASDAQ: PRTK) today announced positive top line data from a pilot rabbit efficacy study evaluating NUZYRA’s effectiveness in the treatment of pulmonary anthrax.

December 19, 2022
·
4 min read
Drug Development

Soligenix Initiates Phase 2 Clinical Trial of SGX302 (synthetic hypericin) for the Treatment of Mild-to-Moderate Psoriasis

Soligenix, Inc. announced today that patient enrollment has been opened for its Phase 2a study (protocol number HPN-PSR-01) evaluating SGX302 (synthetic hypericin) in the treatment of mild-to-moderate psoriasis.

December 19, 2022
·
12 min read
Drug Development

Wave Life Sciences Provides Positive Update on Proof-of-Concept Study for WVE-N531 in Duchenne Muscular Dystrophy

Wave Life Sciences Ltd. announced today a positive update from the initial cohort of the Phase 1b/2a proof-of-concept study of WVE-N531 in three boys with Duchenne muscular dystrophy (DMD) amenable to exon 53 skipping.

December 19, 2022
·
8 min read
Business

Aruna Bio Announces Appointment of Mike Ryan to its Board of Directors

Aruna Bio, Inc., a leader in the development of neural exosome-based therapeutics for the treatment of neurodegenerative diseases, today announced the appointment of Mike Ryan to its Board of Directors, effective immediately.

December 19, 2022
·
2 min read